The Psychedelics Newsletter

COMPASS Pathways' new CEO Kabir Nath, A$250m VC fund created to support psychedelic healthcare, UK-based Awakn Life Sciences expands into US.

The kids are not alright, A need for 100,000 psychedelic-assisted therapists, NHS boosts children's mental health workforce by 40%

The power of bipartisan support, Canadian government sued over psilocybin access, The application of psychedelic medicines in psychiatry

Braving the bear market - investment in psychedelic healthcare, US administration expects psychedelic therapy in two years, NZ government grants MindBio NZ$1.4m

A public listing in psychedelic healthcare, Serotonin hypothesis of depression debased, The commercial potential of psychedelic medicine.

Access to psilocybin in Canada, The life of psychedelic researcher Ann Shulgin, Controlled study shows benefits of microdosing

Training psychedelic therapists, Filament Health announces C$2.5m private placement, MAPS starts study on MDMA-assisted group therapy.

Kernel Flow and the need for neuroimaging data, Veterans Affairs studies psychedelic medicines, Colorado activists file psilocybin ballot initiative.

Psych Capital lists on Aquis Exchange, Australian Capital Territory to decriminalise drug possession, EMCDDA releases annual report for 2022.

Psych Capital lists on Aquis Exchange, Australian Capital Territory to decriminalise drug possession, EMCDDA releases annual report for 2022.

Psychedelic-assisted therapy at home, How psychedelic medicines might treat depression, Former Chief of Australian Defence Force advocates for MDMA therapy.

Oregon’s Psilocybin Services Act, British Columbia to decriminalise possession of illicit drugs, The UK’s opportunity in psychedelic healthcare.